Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2380-2386

  Singh, Seema ^a   Sadanandam, Anguraj ^a   Nannuru, Kalyan C ^a   Varney, Michelle L ^a   Mayer Ezell, Rosemary ^b   Bond, Richard ^b   Singh, Rakesh K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SCH 479833; SCH 527123; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; BENZAMIDES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CYCLOBUTANES; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SKIN NEOPLASMS;

EID: 65249183876     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2387     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71 -96.
2. Ries LA,Wingo PA, Miller DS,etal. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88:2398-424.
3. Lee JA. Trends in melanoma incidence and mortality. Clin Dermatol 1992;10:9-13.
4. Lee JE. Factors associated with melanoma incidence and prognosis. Semin Surg Oncol 1996;12:379-85.
5. Clark WH, Jr., Elder DE, Guerry D, Epstein MN, Greene MH, Van HM. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. HumPathol1984;15:1147-65.
6. Clark WH. Tumour progression and the nature of cancer. Br J Cancer 1991;64:631-44.
7. Herlyn M. Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. Int J Cancer 2006;118:523-6.
8. Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002;1:19-25.
9. Matsushima K, Oppenheim JJ. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine1989;1:2-13.
10. Miller MD, Krangel MS. Biology and biochemistry of the chemokines: a family of chemotactic and inflam- matory cytokines. Crit Rev Immunol 1992;12:17-46.
11. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene " intercrine" cytokine family. Annu Rev Immunol 1991;9:617-48.
12. Bar-Eli M. Roleofinterleukin-8in tumorgrowth and metastasis of human melanoma. Pathobiology1999;
13. Li A, Dubey S,VarneyML,Singh RK. Interleukin-8-inducedproliferation, survival,andMMP productionin CXCR1 and CXCR2expressing human umbilical vein endothelial cells. MicrovascRes2002;64:476-81.
14. Singh RK,Varney ML. IL-8 expression in malignant melanoma: implications in growth and metastasis. Histol Histopathol 2000;15:843-9.
15. Schadendorf D, MollerA, Algermissen B,Worm M, Sticherling M, Czarnetzki BM. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993;151: 2667-75.
16. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nudemice. Cancer Res1994;54:3242-7.
17. Singh RK, Varney ML. Regulation of interleukin 8 expression in human malignant melanoma cells. Cancer Res1998;58:1532-7.
18. VarneyML,LiA,DaveBJ,BucanaCD,Johansson SL,SinghRK. ExpressionofCXCR1andCXCR2 receptors in malignant melanoma with different meta- static potential and their role in interleukin-8 (CXCL- 8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis2003;20:723-31.
19. BertiniR,AllegrettiM,BizzarriC,etal.Noncompe- titive allosteric inhibitors of the inflammatory chemo- kine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 2004; 101:11791 -6.
20. WhiteJR, Lee JM, Young PR, et al. Identification ofa potent, selective non-peptide CXCR2antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem1998;273:10095-8.
21. Thatcher TH, McHugh NA, Egan RW, et al. Role of CXCR2in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 2005;289: L322-8.
22. Gonsiorek W, Fan X, Hesk D, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2antagonist. J Pharmacol Exp Ther 2007;322:477-85.
23. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22: 3099-108.
24. Li A,VarneyML,Singh RK. Expressionofinterleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001;7:3298-304.
25. VarneyML,JohanssonSL,SinghRK.Distinctex- pression of CXCL8 and its receptors CXCR1 and CXCR2and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006;125:209-16.
26. Hall PA, Levison DA,Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-94.
27. Gavrieli Y, ShermanY, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119: 493-501.
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. NatMed1995;1:27-31.
29. Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007;26:453-67.
30. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003; 104:527-32.
31. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998;95:10820-5.
32. Oapos;Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the micro- environment. Biochem J 2008;409:635-49.
33. Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. J Immunol 2000;165:5269-77.
34. Moser B, Loetscher P. Lymphocyte traffic control bychemokines. NatImmunol 2001;2:123-8.
35. Peiper SC, Wang ZX, Neote K, et al. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack theerythrocytereceptor.JExpMed1995;181:1311 -7.
36. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170: 3369-76.
37. Ramjeesingh R, Leung R, Siu CH. Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J 2003;17:1292-4.
38. Chuntharapai A, Kim KJ. Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. J Immunol 1995;155: 2587-94.
39. Quan JM, Martin TR, Rosenberg GB, Foster DC, Whitmore T, Goodman RB. Antibodies against the N- terminus of IL-8 receptor A inhibit neutrophil chemotaxis. Biochem Biophys Res Commun 1996;219: 405-11.
40. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999;79:143-80.
41. Zhuang L, Lee CS, Scolyer RA, et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005;58: 1163-9.
42. Chapman RW, Minnicozzi M, Celly CS, et al. A novel, orally active CXCR1/2receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322:486-93.
43. Kurdowska A, NobleJM, Grant IS, Robertson CR, Haslett C, Donnelly SC. Anti-interleukin-8 autoanti- bodies in patients at risk for acute respiratory distress syndrome. Crit Care Med 2002;30:2335-7.
44. Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-α in psoriasis. Am J Pathol 1991;138: 129-40.
45. Woods JM, Katschke KJ, Jr.,Tokuhira M, et al. Reduction of inflammatory cytokines and prostaglandin E2by IL-13 gene therapy in rheumatoid arthritis syno- vium.J Immunol2000;165:2755-63.